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Abstract 
Background: Although interventional management of malignant central airway obstruction (mCAO) 
is well established, its impact on survival and quality of life (QoL) has not been extensively studied.  
Aim: We prospectively assessed survival, QoL and dyspnea (using validated EORTC questionnaire) 
in patients with mCAO 1 day before interventional bronchoscopy, 1 week after and every 
following month, in comparison to patients who declined this approach. 
Material/Patients/Methods: 36 patients underwent extensive interventional bronchoscopic 
management as indicated, whereas 12 declined. All patients received full chemotherapy and 
radiotherapy as indicated. Patients of the 2 groups were matched for age, comorbidities, type of 
malignancy and level of obstruction. Follow up time was 8.0±8.7 (range 1-38) months.  
Results: Mean survival for intervention and control group was 10±9 and 4±3 months respectively 
(p=0.04). QoL improved significantly in intervention group patients up to the 6th month (p<0.05) 
not deteriorating for those surviving up to 12 months. Dyspnea decreased in patients of the 
intervention group 1 month post procedure remaining reduced for survivors over the 12th month. 
Patients of the control group had worse QoL and dyspnea in all time points. 
Conclusions: Interventional management of patients with mCAO, may achieve prolonged survival 
with sustained significant improvement of QoL and dyspnea. 
Key words: lung cancer, intervention, quality of life. 
Introduction 
Malignant tumors may produce central airway 
obstruction (CAO) causing severe dyspnea, 
significant morbidity and mortality.[1] Lung cancer 
patients develop CAO in as much as 30% of cases 
while up to 40% of the deaths are attributed to 
loco-regional progression.[2] Chemo- and 
radio-therapy alone, seldom can alleviate airway 
obstruction due to non-small cell lung cancer 
(NSCLC). Most patients present at advanced stage 
while surgical interventions are rarely indicated for 
tumors of the trachea and main carina. In these cases, 
interventional therapeutic bronchoscopy remains an 
important alternative method for airway 
management.[3-5]  
Reported survival of patients with untreated 
malignant CAO usually ranges from 1 - 2 months with 
many of them dying of asphyxia or on mechanical 
ventilation.[6] Although the palliative effect of 
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endoscopic management of mCAO is well 
established[7], the long-term effect of these techniques 
has seldom been examined in terms of quality of life 
(QoL) and survival. Several authors have argued that 
temporary relief of dyspnea may lead to prolonged 
suffering from the patient’s point of view.[8] It is 
therefore necessary to elucidate whether there is a 
clear QoL and survival benefit after interventional 
management in patients with inoperable malignant 
CAO. 
Main reasons for lack of prospective, controlled 
studies on survival and QoL should be 
methodological and ethical issues. Most studies 
investigate partially dyspnea and performance status 
scores but not overall QoL.[9-18] To the authors’ 
knowledge there are only two prospective studies 
regarding multimodality approach in malignant CAO 
that include QoL questionnaires but without 
comparing the results to standard oncologic treatment 
nor elucidating the impact on survival or QoL.[19-21]  
Our aim was to prospectively assess the effect of 
interventional bronchoscopic procedures when added 
to the standard oncologic treatment, in patients with 
inoperable mCAO. Primary objectives included 
assessment of dyspnea and overall QoL, as well as 
survival, in comparison to patients who declined 
interventional management and thus acted as control 
group. Secondary objective was to identify 
pre-procedural clinical, radiological or endoscopic 
characteristics which might correlate with poor 
post-procedural outcome. We hypothesized that 
re-establishing airway patency in symptomatic 
patients with inoperable mCAO would result in 
substantial symptomatic relief, improved QoL and 
increased survival.  
Methods  
Study Design  
This is a prospective study performed over a 3 
years period at a University Hospital. Approval was 
obtained from the Hospital’s ethical committee and 
patients gave signed informed consent before 
enrolment. Patients declining interventional 
management were also evaluated and formed the 
control group.  
Subjects  
All consecutive patients symptomatic due to 
inoperable malignant CAO, other than small cell lung 
cancer, were initially evaluated with thorax CT and 
video-bronchoscopy. Indication for interventional 
management was considered after interdisciplinary 
counselling with interventional pulmonologist, 
thoracic surgeon and oncologist. Patients were 
excluded if other medical conditions could be 
responsible for the symptoms, if they had irreversible 
bleeding diathesis, severe cardiopulmonary 
compromise or inability to tolerate bronchoscopy. The 
patients underwent bronchoscopic recanalization of 
the airway (Intervention group) and subsequently 
followed standard oncologic chemo-radio therapy, 
according to international guidelines. If the patients, 
for any reason, declined the interventional approach, 
then sole standard oncologic management with 
chemo-radio therapy was offered (Control group). All 
patients were followed for QoL and performance 
status every month up to their death.  
 Interventional Bronchoscopic procedures  
Both flexible and rigid bronchoscopy were used, 
applying all available in our institution interventional 
modalities (namely electro-cryotherapy, rigid 
bronchoscopy and stent placement), according to the 
specific situation and the published evidence.[1, 4, 5] 
The procedure was considered successful when 
complete re-establishment of the airway patency was 
achieved with post-intervention lumen 80-100% of 
normal width. Partially successful if the 
post-intervention patency was 50-80%, and 
unsuccessful if the patency remained less than 50% of 
normal width. In case of relapse of the stenosis and 
worsening of the symptoms during follow up, 
interventional bronchoscopy was repeatedly 
performed as needed to re-establish patency.  
 QoL and Symptom assessment  
 All patients were assessed before enrolment 
with the Eastern Cooperative Oncology Group 
(ECOG) score for the performance status while 
dyspnea and QoL were assessed with the European 
Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire (EORTC QLQ-C30) 
being the most frequently used and well documented 
in European countries and validated in Greek 
language.[22-27] EORTC QLQ-C30 consists of five 
functional and three symptom scales, as well as a 
specific lung component with 15 questions assessing 
respiratory symptoms in detail. Dyspnea is assessed 
both by the overall questionnaire and the lung 
component questions (LC dyspnea). The initial 
evaluation was followed by an assessment 1 week 
after establishment of airway patency for the 
intervention group and then every following month 
for both groups until eventual death of the patients.  
Statistical Analysis  
All continuous variables are presented by mean 
± SD. Normality of distribution was checked by 
Kolmogorof-Smirnof test. Continuous variables were 
compared by unpaired Student’s t-test or 
Mann-Whitney U test when appropriate. Qualitative 
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variables were compared by χ2 or Fisher exact test. 
The within-patient changes of the intervention group 
before and after the intervention were evaluated with 
paired t-test or paired Wilcoxon test when 
appropriate. Within-patient changes in both groups 
were analyzed using Linear Mixed Effects (LME) 
Modeling. 
 Kaplan-Meier method was used to compare 
survival between intervention and control group. 
Survival time was defined as time from the 
endoscopic diagnosis of inoperable malignant CAO 
until death. The two groups were compared using the 
log-rank test. The direct effect of the intervention 
upon overall patient survival was analyzed and 
quantified through Cox Proportional Hazards 
modeling. P values <0.05 were considered significant.  
Results  
During the 3 years study period 53 patients were 
enrolled in the study. Two subjects were excluded 
because after interventional bronchoscopic 
management, they qualified for curative surgical 
treatment. 5 patients presenting with metastatic 
extra-thoracic malignancy were analyzed separately. 
Thus the final analysis was performed on 46 patients 
(38 males) aged 66 ±11 years.  
Thirty-four patients with NSCLC underwent 
extensive interventional bronchoscopic management 
as indicated (intervention group), whereas 12 
declined endoscopic treatment (control group) (Table 
1). Patients of the 2 groups did not statistically differ 
in terms of age, gender, type or stage of malignancy 
and presence of atelectasis, time between diagnosis 
and enrollment (Table 1). There was a difference 
regarding the level of obstruction, which in the 
intervention group patients was more often located 
centrally than in the patients of the control group. 
Diagnosis of COPD was less often reported in the 
intervention group, although in this group dyspnea 
severity was worse.  
Following intervention (n=34), most patients had 
an improvement in their airway diameter. 14 patients 
(41%) were considered to have had a successful 
procedure, 17 patients (50%) had only partially 
successful procedure and in 3 patients (8.8%) the 
procedure was considered unsuccessful. Nine 
patients underwent retreatment after 5 ± 4 (range 
1-11) months.  
Overall follow up time was 8.6±8.5 (range 1-43) 
months. Seven patients are still alive (5 in the 
intervention group and 2 in the control group) 
followed for 14 ± 16 (range 1-43) months. Mean 
survival time for intervention and control group was 
10±9 and 4±3 months, respectively (log rank p=0.005) 
(Figure 1). The hazard ratio was modeled through cox 
proportion hazards modeling where it was observed 
that the death hazard increases by 2,93 times without 
interventional management of CAO (p=0.009).  
 
 
 
Table 1. Baseline characteristics of the patients.  
  Intervention 
Group (n=34)  
Control Group 
(n=12)  
p  
Age  (years)  65±12  66±8  0,96  
Gender  n, (%)        
0,66  male  27 (79,4%)  11 (91,7%)  
female  7 (20,6%)  1 (8,3%)  
Comorbidities  n, (%)        
0,17  
  
yes  20 (58,8%)  10 (83,3%)  
no  14 (41,2%)  2 (16,7%)  
COPD         
0,013  
  
yes  8 (23,5%)  8 (66,7%)  
no  26 (76,5%)  4 (33,3%)  
CHF        
1,00  
  
yes  6 (17,6%)  2 (16,7%)  
no  28 (82,4%)  10 (83,3%)  
ICD        
1 
  
yes  8 (23,5%)  3 (25%)  
no  26 (76,5%)  9 (75%)  
Long term oxygen therapy        
0,72  yes  11 (32,4%)  3 (25%)  
no  23 (67,6%)  9 (75%)  
Histotype of Lung Cancer 
Malignancy n,(%)  
      
  
0,76  squamous   25 (75,8%)   8 (66,7%)  
adenocarcinoma  5 (15,2%)  3 (25%)  
large cell carcinoma  1 (3%)  0  
non differentiated  1 (3%)  1 (8,3%)  
other  1 (3%)  0  
Stage of Malignancy n,(%)        
T3  9 (26,5%)  1 (8,3%)  0,41  
  T4  25 (73,5%)  11 (91,7%)  
 N0   2 (5,9%)   0 (0%)    
0,50  
  
  
N1  4 (11,8%)  3 (25%)  
N2  18 (52,9%)  7 (58,3%)  
N3  10 (29,4%)  2 (16,7%)  
 M0   24 (70,6%)   5 (41,7%)   0,09  
M1  10 (29,4%)  7 (58,3%)  
Atelectasis  n,(%)        
0,17  yes  16 (48,5%)  9(75%)  
no  17 (51,5%)  3(25%)  
Level of Obstruction n,(%)        
<0.001  trachea  28(52,9%)  1(8,3%)  
main stem  15(44,1%)  6(50%)  
lobar bronchi  1(2,9%)  5(41,7%)  
ECOG  score  2.7±1  2±1.3  0,1  
Global Health  42±28  44±28  0,8  
Physical Function  41±29  51±29  0,29  
Dyspnea  79±26  53±30  0,005  
LC dyspnea  66±30  50±33  0,13 
LC coughing  66±30  61±24  0,64  
LC Hemoptysis  33±29  22±29  0,26 
COPD: Chronic Obstructive Pulmonary Disease, CHF: Chronic Heart Failure, ICD: 
Ischemic Coronary Disease, NSCLC: non-small cell lung cancer, ECOG: Eastern 
Cooperative Oncology Group, LC: Lung Component of EORTC questionnaire. 
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Figure 1. Kaplan Meier curves showing survival after diagnosis of airway 
obstruction in patients of the intervention group as compared to the control 
group.  
 
As shown in Table 2, global health EORTC scores 
compared with pre-intervention values, significantly 
improved in all patients of the intervention group one 
week post intervention and remained improved up to 
the 3rd month, in all surviving patients (n=26) 
(p<0.05). EORTC scores did not deteriorate in patients 
surviving up to 12 months after the intervention 
(n=9) as compared to one week post intervention 
values (p>0.05). Dyspnea significantly decreased in all 
surviving patients of the intervention group one 
month after the procedure (n=34) (p<0.05). For those 
surviving over the 6th (n=19) and over the 15th (n=6) 
month dyspnea remained significantly improved 
(p<0.05). Physical function immediately improved 
post intervention remaining high even 12 months post 
intervention for surviving patients (p<0.05). 
Coughing and hemoptysis decreased significantly in 
intervention group patients remaining low, up to the 
9th month (Table 2). 
Regarding pre-intervention patient 
characteristics, patients initially presenting with 
atelectasis had greater and sustained improvement in 
EORTC global health component at 1 month 
compared to those without atelectasis (+26.1±29.3 vs 
3.3±30.6; p=0.047). All other pre-intervention 
parameters (age, gender, type of malignancy, level of 
CAO, metastases or co-morbidities, LTOT, previous 
chemo- radio therapy, base line EORTC assessment) 
did not significantly influence outcomes.  
Between the 1st and the 6th month post 
intervention, control group patients had significantly 
lower quality of life (p<0.05) and higher dyspnea 
(p<0.05) (Figure 2, Table 3). After 6th month, not 
enough control group patients were alive to conduct 
comparative analysis.  
Linear Mixed-effects Modeling was performed 
for both groups to confidently model the patient’s 
course through time as described by specific 
parameters. The parameters analyzed were Global 
QoL, Physical Function, Dyspnea, LC-Dyspnea, 
LC-Cough and LC-Haemoptysis. The 
Intervention-Group was modeled from 1 week after 
the intervention onwards while the control group was 
modeled from the whole dataset (Table 4). Global QoL 
parameter reveals that, although control group 
patients had significantly lower QoL, rates of 
deterioration for the two groups did not differ 
significantly (-3,26 vs -2,07). Regarding the 'Physical 
Function' parameter, the intervention group patients 
deteriorate at a slower rate than those of the control 
group (-2,89 vs -1,47) while regarding the 'Dyspnea' 
parameter, the intervention group patients deteriorate 
at a much slower rate than those of the control group 
(2,73 vs 4,34 respectively for overall dyspnea and 2,96 
vs 2,04 for LC dyspnea). 'LC-Cough' & 
'LC-Haemoptysis' did not present a linear pattern 
versus time, adequate for this analysis.  
 
Table 2. ECOG scores and the QoL, physical function, dyspnea, LC dyspnea, LC coughing and LC hemoptysis values of the  EORTC 
questionnaire in the surviving patients of the intervention group  up to 18 months post intervention.  
  pre intervention  
value  (n=34)  
post 1  
week 
(n=34)  
post 1  
month   
(n=34)  
post 3  
months   
(n=26)  
post 6 
months  
(n=19)  
post 9 
months  
(n=16)  
post 12 
months  (n=9)  
post 15 
months  
(n=6)  
post 18  
months   
(n=3)  
ECOG  2.7±1  2 ±1.4*  2.4±1.3*  2.3±1.5 2.1±1.5 2.3±1.5  1.4±1.1*  2.5±1.5  2±1 
Global Health  42±28  64±18*  57±20*  57±26* 62±21 48±32  57±24  60±21  47±19  
Physical Function  41±29  55±32*  55±31*  57±36*  63±30  49±34  67±22*  54±20  51±31  
Dyspnea  79±26  35±34*  39±37*  45±36*  37±37*  47±41*  41±22*  39±39*  67±58  
LC dyspnea  66±30  33±27*  35±29*  33±34*  32±24*  50±37  41±17 * 41±33  50±35 
LC coughing  66±30  42±29*  42±37*  42±30*  31±25*  40±38*  37±35  49±35  22±38  
LC Hemoptysis  33±29  15±19*  12±22*  10±19*  31±25  18±25 * 11±17* 22±27  11±19  
ECOG: Eastern Cooperative Oncology Group, LC: lung component ,values are expressed as mean±SD, * significant compared to pre-intervention values.  
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Figure 2. Global QoL (QL2), Physical function (PF2) and Level of Dyspnea (DY) assessed with the EORTC questionnaire in patients of the intervention group in 
comparison to the control group. (Error bars represent mean   ±  2SE). 
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Table 3. Comparison of the two groups at base line and during follow up to 6 months.  
  Baseline  Post 1 month  3months  6months  
Global Health          
 Intervention Group  42±28 (n=34)  57±21 (n=31)  57±26 (n=23)  62±21 (n=17)  
 Control Group  44±28 (n=12)  30±21 (n=10)*  29±17 (n=6)*  28±19 (n=3)* 
Physical Function          
 Intervention Group  41±29 (n=34)  55±31 (n=31)  57±36 (n=23)  63±30 (n=17)  
 Control group  51±29 (n=12)  29±24 (n=10)*  34± 32 (n=6)*  13±23 (n=3)* 
Dyspnea          
 Intervention Group  79±26 (n=34)  39±37 (n=31)  45±36 (n=23)  37±37 (n=17)  
 Control Group  53±30 (n=12)*  57±35 (n=10)*  61±25 (n=6)*  78±38 (n=3)*  
LC dyspnea          
 Intervention Group  66±30 (n=34)  35±29 (n=31)  33±34 (n=23)  32±25 (n=17)  
 Control Group  50±33 (n=12)  65±27 (n=10)*  70± 31 (n=6)*  78±11 (n=3)*  
LC coughing          
 Intervention Group  66±30 (n=34)  42±37 (n=31)  42±31 (n=23)  31±25 (n=17)  
 Control Group  61±24 (n=12)  57±32 (n=10)  44±17 (n=6)  11±19 (n=3)  
LC Hemoptysis          
 Intervention Group  33±29 (n=34)  12±22 (n=31)  10±19 (n=25)  6±13 (n=17)  
 Control Group  22±29 (n=12)  13±17 (n=10)  11±17 (n=6)  44±51 (n=3)  
 
 LC Lung Component, *significantly different when compared to intervention group. 
 
Table 4. Linear Mixed-Effects (LME) Analysis of the intervention and control groups for specific parameters.  
    Intervention Group Control Group 
  Intercept  Coefficient  P-value  Time to Intervention Group 
Initial Values (months)  
Intercept  Coefficient  P-value  
Global Health  62,21 -3,26  <0.001  6,87  29,53  -2,07  0,057  
Physical Function  56,53  -2,89  0.001  5,21  29,92 -1,47  0,466  
Dyspnea  35,37  2,73  0,007  21,17  53,86  4,34  0,006  
LC-Dyspnea  29,91  2,96  0.001  12,49  69,09 2,04  0,072  
LC-Cough  38,74  0,65  0,408  NA  67,83  -6,77  0,007  
LC-Haemoptysis  10,83  0,09  0,761  NA  6,37  3,39  0,303  
LME analysis was performed in order to confidently quantify the patients’ course over time as described by each parameter. Intercepts and coefficients are characteristics of 
the linear models. Intercepts indicate the value of each parameter at Time=0. Coefficients are an indication of the rate of change of each parameter as time passes on a 
monthly basis. The p-values indicate the validity of the modelling. “Time to Intervention-Group Initial Values” parameter indicates the time lapse in months as calculated by 
the linear model, until the intervention group patients reached the pre-intervention values; hence it is an indication of the time 'gained' by the patients in terms of quality of 
life, dyspnea severity etc. and was calculated only for the parameters having a statistically significant linear model. 
 
Discussion  
Patients with advanced NSLC and CAO have 
poor prognosis and left untreated their survival 
usually does not exceed few weeks.6 Although 
therapeutic bronchoscopy has been previously 
reported to relieve symptoms of cough, dyspnea and 
hemoptysis, achieving endoscopic, radiologic, 
spirometric and QoL improvements, it is generally 
considered as a palliative measure not able to 
essentially prolong patients’ survival.[8, 17-21]  
The present prospective study provided detailed 
assessment of the impact of interventional 
bronchoscopy in patients with inoperable malignant 
CAO versus matched patients undergoing only 
standard oncologic treatment. Using a validated tool 
we were able to assess symptoms, overall and 
respiratory specific QoL as well as long term survival 
of these patients. The results demonstrate that 
interventional approach may achieve significant and 
sustained QoL and dyspnea improvement together 
with prolonged survival in patients with airway 
obstructing malignancies.  
In previous studies assessing the impact of 
bronchoscopic treatment in patients with inoperable 
malignant CAO, either only one bronchoscopic 
modality was studied each time or no other systemic 
therapy towards their malignancy was 
administered.[6, 17, 20] However, interventional 
bronchoscopy using all available modalities together, 
may serve as a bridge to radiation and/or 
chemotherapy, allowing for a durable relief of 
symptoms.[11] All our patients improved clinically 
after the intervention and were able to sustain further 
oncologic treatment while two subjects even qualified 
for curative surgical treatment.  
In our study cohort although all patients were 
offered the option of therapeutic bronchoscopy after 
interdisciplinary counseling several declined 
bronchoscopic treatment. These were patients with 
more distal level of obstruction, higher prevalence of 
COPD and lower grade of dyspnea according to the 
general component of the EORTC questionnaire. We 
hypothesize that prior dealing with COPD symptoms 
in combination with fear of complications, given their 
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lower level of dyspnea, and less prominent 
obstructive symptoms was the main drawback of 
these patients to accept bronchoscopic treatment. 
A limitation of our study is the small population 
rendering subgroup analysis limited albeit useful for 
generating hypotheses. Furthermore, the results of the 
QoL questionnaire were not correlated with objective 
respiratory functional testing. This would have been 
quite demanding given the advanced disease and the 
level of dyspnea of most patients.  
There are several potential explanations of the 
survival benefit observed in our patient population 
undergoing interventional management: Timely 
management of malignant CAO may prevent or delay 
lethal complications such as post-obstructive 
pneumonia, sepsis and respiratory insufficiency, thus 
allowing adjuvant chemotherapy and external beam 
radiation to prolong survival.[21] In our study, 
patients treated bronchoscopically survived more 
than twice as long as patients treated only by standard 
oncologic treatment.  
In a recent study Oviat et al. showed significant 
improvement of 6 min walking distance, FEV1 and 
FVC, dyspnea and QoL scores by day 30 
post-intervention, not being able whatsoever to report 
longer follow up of their patients.[19] Similarly, 
Amjadi et al. reported decreased dyspnea but not 
significant QoL benefit one month post-intervention20. 
However, in our study in which patients were 
meticulously followed up to their death, validated 
EORTC QLQ-C30 QoL questionnaire produced much 
more encouraging data.  
Overall, dyspnea, significantly decreased one 
month post-intervention and as LME analysis reveals 
it would take approximately 21 months for the 
patients of the intervention group to reach their 
pre-intervention values. This is extremely 
considerable given that average survival time of the 
control group is only 4 months and that of the 
intervention group is approximately 10 months. This 
means that most of the patients of the intervention 
group do not survive long enough to experience 
dyspnea as severe as the one they experienced before 
the intervention. Equally important, 'Global Quality 
of Life' measurements of the intervention group 
significantly improved immediately after 
intervention, while deterioration rate remained close 
to the one of the control group. This is expected since 
the intervention of the current study is only a means 
to palliate symptoms and facilitate other applied 
therapeutic strategies. Additionally LME analysis 
revealed that it takes approximately 7 months for the 
intervention group patients to reach their 
pre-intervention 'Global Quality of Life' values. 
Finally, 'Physical Function' improved in all patients of 
the study group immediately after intervention. LME 
analysis reveals that the deterioration rate is lower in 
the intervention group and that it would take 
approximately 5 months for the patients of the 
intervention group to reach their pre-intervention 
values.  
To our knowledge there are not any other data in 
the literature reporting dyspnea and QoL assessment 
for such a long follow up period compared or not to a 
control group. Subgroup analysis of the 
pre-procedural clinical, radiological and endoscopic 
characteristics revealed that QoL and Dyspnea 
improvement was greater in patients initially 
presenting with atelectasis. All other parameters did 
not significantly influence treatment outcomes.   
Recent ACCP Lung Cancer Guidelines mention 
several interventional bronchoscopic modalities for 
palliation of dyspnea due to inoperable malignant 
CAO.[28] The results of the present prospective, 
controlled study confirm the considerable benefit of 
interventional bronchoscopic management of such 
patients and make an argument that patients with 
malignant CAO treated endoscopically have less 
dyspnea, better QoL, improved physical function and 
longer survival than patients with oncologic 
treatment alone. Combined interventional and 
oncologic treatment should be considered in any 
multidisciplinary cancer care program and offered to 
all patients with lung cancer and inoperable CAO, 
especially when post-obstructive atelectasis is present. 
Since such an approach is often limited by the lack of 
interventional equipment and skills, the urgent need 
for respiratory physicians’ training in therapeutic 
bronchoscopy and development of interventional 
units is also highlighted.[29] (Figures 3-8) Additional 
treatment with radiotherapy could be used based on 
the patient performance status and local 
interventional prior or after stent 
placement-debulking.[30-36] Multimodality treat-
ment is necessary for patients with central tumors 
local treatment 
should be 
accompanied 
with systematic 
treatment when 
possible. 
 
Figure 3. Argon 
Plasma Coagulation. 
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Figure 4. LASER beam coagulation. 
 
 
Figure 5. Cryoprobe performing debulking of central airways malignnat tumor. 
 
 
Figure 6. Bifurcated silicone stent. 
 
 
Figure 7. Rigid electrocatery. 
 
 
Figure 8. Removal of endobronchial tumor with loop. 
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